NASDAQ$KNSA
Kiniksa Pharmaceuticals Ltd · Q1 2024 earnings
Q1 2024 earnings · · Investor relations
Briefing
Reported first quarter financial results and portfolio execution.
Kiniksa Pharmaceuticals reported strong first quarter 2024 results, driven by an 85% year-over-year increase in ARCALYST net product revenue, reaching $78.9 million. The company has raised its full-year ARCALYST net product revenue guidance to $370 - $390 million and plans to initiate a Phase 2b trial of abiprubart in Sjögren’s Disease in the second half of 2024. Kiniksa expects to remain cash flow positive on an annual basis.
- ARCALYST Q1 2024 net product revenue reached $78.9 million, representing 85% year-over-year growth.
- Increased ARCALYST 2024 expected net product revenue to $370 - $390 million.
- Planned to initiate Abiprubart Phase 2b trial in Sjögren’s Disease in 2H 2024.
- Current operating plan expected to remain cash flow positive on an annual basis.
Headline financials
Revenue & EPS history
Kiniksa · Revenue · Quarterly
$79.9M
Revenue by segment
Kiniksa · $64.8M total across 1 segment · Q3 2023
- ARCALYST$64.8M+94.0%100.0%
Forward guidance
Kiniksa expects ARCALYST net product revenue to be between $370 million and $390 million. The company plans to initiate a Phase 2b clinical trial of abiprubart in Sjögren’s Disease in the second half of 2024 and expects to remain cash flow positive on an annual basis.
Tailwinds
- ARCALYST 2024 net product revenue will be between $370 million and $390 million.
- Phase 2b clinical trial of abiprubart in Sjögren’s Disease planned to initiate in 2H 2024.
- Expectation to remain cash flow positive on an annual basis within current operating plan.
- Belief that using abiprubart to disrupt the CD40-CD154 co-stimulatory interaction is an attractive approach to address multiple autoimmune disease pathologies.
- Belief that all product candidates offer the potential for differentiation.
Headwinds
- Risks arising from the planned redomiciliation of principal holding company from Bermuda to the United Kingdom.
- Delays or difficulty in enrollment of patients in, and activation or continuation of sites for, clinical trials.
- Delays or difficulty in completing clinical trials as originally designed.
- Potential for changes between final data and any preliminary, interim, top-line or other data from clinical trials.
- Inability to replicate results from earlier clinical trials or studies.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2024
+5.3%
Avg return
Earnings day
+5.2%
Avg return
5 days after
+7.8%
Avg return
30 days after
55%
17 / 31 earnings
Positive
+45.8%
Q3 2021
Best reaction
-16.6%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +23.5% | +26.7% | +16.6% | |
| Q4 2025 | -4.7% | -6.1% | -1.3% | |
| Q3 2025 | -2.9% | -8.8% | +4.8% | |
| Q1 2025 | +20.5% | +28.8% | +26.6% | |
| Q4 2024 | +0.5% | +3.3% | +19.0% | |
| Q3 2024 | -16.6% | -18.5% | -19.1% | |
| Q2 2024 | +17.8% | +22.1% | +22.5% | |
| Q1 2024 | +4.4% | +4.6% | +12.1% | |
| Q4 2023 | +1.2% | -3.4% | -5.6% | |
| Q3 2023 | -3.4% | +3.3% | +3.1% | |
| Q2 2023 | +35.2% | +26.8% | +18.1% | |
| Q1 2023 | +24.2% | +24.7% | +29.0% | |
| Q4 2022 | -5.6% | -7.8% | -19.7% | |
| Q3 2022 | +8.6% | +21.7% | +49.3% | |
| Q2 2022 | +17.3% | +29.9% | +14.7% | |
| Q1 2022 | +5.1% | -6.8% | -18.4% | |
| Q4 2021 | -6.8% | -3.4% | -7.2% | |
| Q3 2021 | +45.8% | +41.8% | +8.8% | |
| Q2 2021 | -1.4% | -5.4% | -10.0% | |
| Q1 2021 | -9.0% | -11.4% | -19.4% | |
| Q4 2020 | -6.3% | -11.9% | -28.5% | |
| Q3 2020 | -5.9% | -7.2% | +9.6% | |
| Q2 2020 | +0.8% | -1.2% | -14.7% | |
| Q1 2020 | -7.0% | -9.2% | -0.6% | |
| Q4 2019 | -0.7% | +6.1% | -29.5% | |
| Q3 2019 | +15.7% | +24.5% | +80.8% | |
| Q2 2019 | -2.4% | -12.1% | -9.4% | |
| Q1 2019 | +8.2% | +2.6% | +6.5% | |
| Q4 2018 | -6.1% | -0.2% | +20.2% | |
| Q3 2018 | +11.9% | +5.1% | +6.2% | |
| Q2 2018 | +1.7% | +3.5% | +78.2% | |
| Q1 2018 | — | — | — | |
| Q4 2017 | — | — | — | |
| Q3 2017 | — | — | — | |
| Q2 2017 | — | — | — | |
| Q1 2017 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro